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1. Disease characteristics 46 
1.1 Name of the Disease (Synonyms): 47 
See table 1, column 1 - 'Name of the disease' 48 
 49 
Name of the disease OMIM# of 
the disease 
Cytogenetic 
location 
Associated 
gene(s) 
OMIM# of 
associated 
gene (s) 
Microphthalmia, isolated 1; 
MCOP1 
251600 14q32 - - 
Microphthalmia, isolated 2; 
MCOP2 
610093 14q24.3 VSX2 142993 
Microphthalmia, isolated 3; 
MCOP3 
611038 18q21.32 RAX 601881 
Microphthalmia, isolated 4; 
MCOP4 
613094 8q22.1 GDF6 601147 
Microphthalmia, isolated 5; 
MCOP5 
611040 11q23.3 MFRP 606227 
Microphthalmia, isolated 6; 
MCOP6 
613517 2q37.1 PRSS56 613858 
Microphthalmia, isolated 7; 
MCOP7 
613704 12p13.31 GDF3 606522 
Microphthalmia, isolated 8; 
MCOP8 
615113 15q26.3 ALDH1A3 600463 
Microphthalmia, isolated with 
coloboma 1; MCOPCB1 
300345 Chr.X - - 
Microphthalmia, isolated with 
coloboma 2; MCOPCB2 
605738 15q12-q15 - - 
Microphthalmia, isolated with 
coloboma 3; MCOPCB3 
610092 14q24.3 VSX2 142993 
Microphthalmia, isolated with 
coloboma 4; MCOPCB4 
251505 - - - 
Microphthalmia, isolated with 
coloboma 5; MCOPCB5 
611638 7q36.3 SHH 600725 
Microphthalmia, isolated with 
coloboma 6; MCOPCB6 
613703 8q22.1 
12p13.31 
GDF6 
GDF3 
601147 
606522 
Microphthalmia, isolated with 
coloboma 7; MCOPCB7 
614497 2q35 ABCB6 605452 
Microphthalmia, isolated with 
coloboma 8; MCOPCB8 
601186 15q24.1 STRA6 610745 
Microphthalmia, isolated with 
coloboma 9; MCOPCB9 
615145 4q34.3-35.1 TENM3  610083 
Microphthalmia, isolated with 
coloboma 10; MCOPCB10 
616428 10q23.33 RBP4 180250 
Microphthalmia, isolated with 
corectopia; MCOPCR 
156900 - - - 
Microphthalmia, isolated with 
cataract 1; MCOPCT1 
156850 16p13.3 - - 
Nanophthalmos 1; NN01 600165 11p - - 
Nanophthalmos 2; NN02 609549 11q23.3 MFRP 606227 
Nanophthalmos 3; NN03 611897 2q11-q14 - - 
Nanophthalmos 4; NN04 615972 17q11.2 TMEM98 615949 
Table 1. Overview of disease associated with non-syndromic (isolated and complex) 50 
microphthalmia 51 
 52 
1.2 OMIM# of the Disease:  53 
See table 1, column 2 - 'OMIM# of the disease' 54 
 55 
1.3 Name of the Analysed Genes or DNA/Chromosome Segments and OMIM# of the 56 
Gene(s): 57 
1.3.1 Core genes (irrespective if being tested by Sanger sequencing or next-58 
generation sequencing) 59 
See table 1, column 4 - 'Associated gene(s)' and column 5 - 'OMIM# of associated gene(s)' 60 
 61 
1.3.2 Additional genes (if tested by next-generation sequencing, including whole 62 
exome/genome sequencing and panel sequencing) 63 
See table 2, column 1 - 'Gene’ and column 3 - 'OMIM# of gene' 64 
 65 
Gene Cytogenetic 
location 
OMIM# of 
gene 
Associated disease 
acronym 
OMIM# of the 
disease (where 
applicable) 
BCOR Xp11.4 300485 Microphthalmia, 
syndromic 2 
300166 
BMP4 14q22.2 112262 Microphthalmia, 
syndromic 6 
607932 
CHD7 8q12.2 605806 CHARGE syndrome 214800 
COL4A1 13q34 120130 Brain small vessel disease 
with or without ocular 
anomalies 
607595 
FREM1 9p22.3 608944 Manitoba oculotrichoanal 
syndrome 
248450 
HCCS Xp22.2 300056 Linear skin defects with 
multiple congenital 
anomalies 1 
309801 
HMGB3 Xq28 300193 Microphthalmia, 
syndromic 13 
300915 
MAB21L2 4q31.3 604357 Microphthalmia, 
syndromic 14 
615877 
NAA10 Xq28 300013 Microphthalmia, 
syndromic 1 
309800 
OTX2 14q22.3 600037 Microphthalmia, 
syndromic 5 
610125 
PAX6 11p13 607108 Ocular malformations 
within the MAC spectrum 
- 
PXDN 2p25.3 605158 Cornea opacification and 
other ocual anomalies 
269400 
RARB 3p24.2 180220 Microphthalmia, 
syndromic 12 
615524 
SMOC1 14q24.2 608488 Microphthalmia with limb 
anomalies 
206920 
SOX2 3q26.33 184429 Microphthalmia, 
syndromic 3 
206900 
     
     
TMX3 18q22.1 616102 Microphthalmia with 
coloboma 
- 
VAX1 10q25.3 604295 Microphthalmia, 
syndromic 11 
614402 
YAP1 11q22.1  606608 Ocular coloboma 120433 
Table 2. Additional genes associated with isolated and complex microphthalmia, often with 66 
syndromic features, tested by next-generation sequencing 67 
 68 
1.4 Mutational Spectrum: 69 
Isolated microphthalmia is rare; most patients have associated ocular anomalies (complex), 70 
such as ocular coloboma, cataract, and anterior segment dysgenesis. Nearly 80% of cases 71 
are associated with multisystemic features forming part of a syndrome (1-4). Only isolated 72 
and complex (non-syndromic) microphthalmia will be discussed (see Clinical Utility Gene 73 
Card for syndromic microphthalmia). There is a complex aetiology with chromosomal, 74 
monogenic and environmental causes identified. It is clinically and genetically 75 
heterogeneous and may be inherited in an autosomal dominant, recessive, or X-linked 76 
recessive manner, although most cases of non-syndromic microphthalmia are sporadic. The 77 
occurrence of de novo mutations, mosaicism and incomplete penetrance makes prediction 78 
of the inheritance pattern difficult. Chromosomal duplications, deletions and translocations 79 
have been identified; a locus for autosomal dominant microphthalmia has been mapped to 80 
15q12-15,(5) and for autosomal recessive microphthalmia at 14q32.(6, 7) Autosomal 81 
recessive VSX2 variants (causing MCOP2) account for approximately 2% of isolated 82 
microphthalmia cases, and are predominantly missense. However deletion of exon 3 has 83 
also been described.(8, 9) Autosomal recessive variants in RAX (MCOP3) and ALDH1A3 84 
(MCOP8) can be missense, nonsense or frameshift, with some splice donor variants. Only 85 
missense variants have been found in GDF6 (MCOP4) and GDF3 (MCOP7) and are 86 
inherited in an autosomal dominant manner. Homozygous or compound heterozygous 87 
variants in MFRP (MCOP5) or PRSS56 (MCOP6) are associated with autosomal recessive 88 
posterior microphthalmia, which defines a rare distinct phenotype restricted primarily to the 89 
posterior segment of the eye. Patients with MFRP variants also develop a progressive rod 90 
cone dystrophy. Missense, nonsense and frameshift variants, plus splice donor variants 91 
have been described for both these genes. 92 
 93 
Many specific variants may cause varied phenotypes e.g. NM_001142617.1: c.1157G>A 94 
and c.1156G>A (p.Gly304Lys) in STRA6 causes MCOPCB8 (isolated microphthalmia and 95 
coloboma) and Matthew-Wood syndrome (bilateral anophthalmia with pulmonary agenesis 96 
and other associated systemic defects).(10) Phenotypic findings in patients presenting with 97 
microphthalmia and congenital cataract (MCOPCT1) also include mental retardation and an 98 
individual with congenital heart disease. Patients with OTX2 variants have been described 99 
with specific hippocampal abnormalities and phenotypic findings in patients affected by RAX 100 
variants include developmental delay with autistic features and hypoplastic optic nerve and 101 
chiasm. MCOP4 has been reported in cases as isolated, or associated with skeletal 102 
anomalies, coloboma or polydactyly. Autism and cardiac anomalies have been described as 103 
additional features in a MCOP8-affected Pakistani patient, although these phenotypes may 104 
be unrelated to ALDH1A3 variants. Furthermore, one patient with a variant in the ALDH1A3 105 
gene has been described with posterior coloboma and detached retina and another with 106 
optic nerve and chiasm hypoplasia associated with MCOP8. This makes the genetic 107 
classification system of isolated/complex and syndromic microphthalmia challenging. 108 
  109 
A patient with a 2.7 Mb deletion at 18q22.1, incorporating the gene TMX3, presented with 110 
microphthalmia. Two additional sequence variants have been identified in unrelated patients; 111 
a male with unilateral microphthalmia and retinal coloboma (NM_019022.3: c.116G>A 112 
(p.Arg39Gln)); and a female with unilateral microphthalmia and severe micrognathia 113 
(NM_019022.3: c.322G>A, (p.Asp108Asn)).(11) Consequently, the contribution of TMX3 114 
variants to MCOPCB1 has been suggested but remains to be confirmed. 115 
 116 
Nanophthalmos is a subtype of simple microphthalmos. Autosomal recessive 117 
nanophthalmos-2 (NNO2) has been associated with homozygosity for a nonsense 118 
(NM_031433.3: c.523C>T, (p.Gln175Ter)) or frameshift (NM_031433.3: c.1143insC (p. 119 
Gly383Ter)) variant and compound heterozygosity for a frameshift (NM_031433.3: 120 
c.498delC (p.Asn167Thrfs)) or a missense (NM_031433.3: c.545T>C (p.Ile182Thr)) variant 121 
in MFRP.(12) Additional complications can develop, including angle closure glaucoma, cystic 122 
edema, and retinal detachment. More recently, two segregating missense variants 123 
(NM_015544.2: c.577G>C (p.Ala193Pro); c.587A>C (p.His196Pro)) and a 34 bp 124 
heterozygous deletion ( NM_015544.2: c.236_263+6del34) 125 
c.694_721delAGAATGAAGACTGGATCGAAGATGCCTCgtaagg) in TMEM98 have been 126 
described in autosomal dominant nanophthalmos (NNO4) pedigrees.(13, 14) 127 
 128 
Of the monogenic causes of anophthalmia/microphthalmia, SOX2 has been implicated as a 129 
major causative gene, in which variants account for 15-20% of autosomal dominant 130 
cases.(15) However, patients with SOX2 variants usually present with other systemic 131 
malformations; the contribution of SOX2 variants to isolated microphthalmia specifically, 132 
remains unknown. The majority of SOX2 sequence variants are de novo; nonsense, 133 
missense, frameshift and whole gene deletions have been reported.(16, 17) Like SOX2, the 134 
majority of OTX2 variants are inherited nonsense and frameshift variants leading to 135 
haploinsufficiency, with some reports of whole gene deletions.(18) Patients often present 136 
with additional brain abnormalities. In view that variants in the genes listed in Table 2 cause 137 
a wide range of ocular phenotypes with different expressivity, their molecular screening must 138 
be recommended.  139 
 140 
All data was mined from primary literature or curated genomic and phenotype databases, 141 
including ClinVar®, public archive of interpretations of clinically relevant variants  142 
(http://www.ncbi.nlm.nih.gov/clinvar/); GeneReviews® 143 
(http://www.ncbi.nlm.nih.gov/books/NBK1116/); The Human Gene Mutation Database, 144 
HGMD® (http://www.hgmd.org/) and Online Mendelian Inheritance in Man, OMIM® 145 
(http://omim.org/). Novel data should be shared through these databases. They were last 146 
accessed on 15th November 2016. 147 
 148 
1.5 Analytical Validation 149 
Sequencing of both DNA strands. Disease-causing variants should be confirmed using 150 
genomic DNA from a new extraction. Causative variants found with next-generation 151 
sequencing should be verified using Sanger sequencing or other specific molecular methods 152 
(e.g. PCR digest); for further details, see the Eurogentest Guideline. It is important to look for 153 
segregation to determine whether the variant is de novo in isolated cases, providing a higher 154 
likelihood it is pathogenic. In clinical practise, array comparative genomic hybridisation 155 
(aCGH) or multiplex ligation dependent probe amplification assay (MLPA) may be performed 156 
initially to detect deletions or duplications. Some molecular service labs also offer 157 
fluorescence in situ hybridisation (FISH) to identify rearrangements or copy number 158 
variation.  159 
 160 
1.6 Estimated Frequency of the Disease 161 
(Incidence at birth ("birth prevalence") or population prevalence. If known to be variable 162 
between ethnic groups, please report): 163 
The birth prevalence of microphthalmos ranges from 2 to 17 per 100,000 (19-24). In a 164 
prospective UK incidence study over 18 months, 135 confirmed cases of microphthalmia, 165 
anophthalmia and ocular coloboma (MAC) were reported in children under 16 years of age; 166 
microphthalmia was present in 66 (48.9%) children; isolated in 31 (23%) and mixed in 35 167 
(25.9%) (25). Microphthalmia was reported in 3.2-11.2% of blind children worldwide in 2006 168 
(4).  169 
 170 
Epidemiological data suggests risk factors for microphthalmia are maternal age over 40, 171 
multiple births, infants of low birth weight and low gestational age.(4, 23, 26) There is no 172 
predilection with regards to race or gender.(23, 26) Isolated microphthalmia is most 173 
commonly unilateral.(26)  174 
 175 
1.7 Diagnostic Setting: 176 
 Yes. No. 177 
A. (Differential) diagnostics    178 
B. Predictive Testing    179 
C. Risk assessment in Relatives    180 
D. Prenatal    181 
 182 
Comment: Due to time constraints, such as pregnancy, panel diagnostic or Whole Exome 183 
Sequencing or Whole Genome Sequencing (WES/WGS) filtering is preferred if there is a 184 
request for prenatal diagnosis (which is rare).185 
2. Test characteristics 186 
 187 
 188 
2.1 Analytical Sensitivity 189 
(proportion of positive tests if the genotype is present in the analyte) 190 
2.1.1 if tested by conventional Sanger sequencing 191 
Less than 100%. The proportion is likely <100%, because primers may be localised on 192 
sequences containing SNVs or rare variants, which results in a preferential amplification of 193 
one allele (allele drop out). A supplementary deletion/duplication diagnostic test should be 194 
performed for genes with a known proportion of large genomic deletions/duplications as 195 
outlined in section 1.5. 196 
 197 
2.1.2 if tested by Next-generation sequencing 198 
Less than 100%. The proportion is likely <100%, because there might be disease-causing 199 
variants in regions that could not be enriched and/or sequenced by next-generation 200 
sequencing due to suboptimal coverage of some regions of interest with this technology but 201 
depending on next-generation sequencing strategy. If amplicon-based enrichment strategies 202 
are being used, primers may be localized on SNVs or rare variants, which results in 203 
preferential amplification of one allele. In patients with a highly suggestive phenotype in 204 
whom testing for specific gene alterations proves negative, a supplementary 205 
deletion/duplication diagnostic test should be performed for genes with a known proportion 206 
of large genomic deletions/duplications as outlined in section 1.5. 207 
. 208 
 209 
2.2 Analytical Specificity 210 
(proportion of negative tests if the genotype is not present) 211 
2.2.1 if tested by conventional Sanger sequencing 212 
Nearly 100%. False positives may at the most arise due to misinterpretation of rare 213 
polymorphic variants.  214 
 215 
2.2.2 if tested by Next-generation sequencing 216 
Less than 100%. The risk of false positives due to misinterpretation of rare polymorphic 217 
variants may be higher compared with Sanger sequencing because of greater number of 218 
analysed genes.  219 
 220 
2.3 Clinical Sensitivity 221 
(proportion of positive tests if the disease is present) 222 
The clinical sensitivity can be dependent on variable factors such as age or family history. In 223 
such cases a general statement should be given, even if a quantification can only be made 224 
case by case. 225 
 226 
2.3.1 if tested by conventional Sanger sequencing 227 
Of those patients that undergo genetic testing of known causative genes with Sanger 228 
sequencing, less than 10% of patients with isolated microphthalmia receive a molecular 229 
diagnosis and these are predominantly bilateral severe cases.  230 
   231 
Most studies group microphthalmia with MAC and therefore the most common causative 232 
genes are SOX2, OTX2, PAX6 and GDF6 contributing up to 10%, 3%, 2.5% and 8%, 233 
respectively.(27) These are often syndromic cases and so the actual contribution to isolated 234 
microphthalmia is likely to be much lower. 235 
 236 
2.3.2 if tested by Next-generation sequencing 237 
See 2.3.1. Mutation detection rates are higher when combined WES with array aCGH and 238 
high resolution analysis of intragenic microdeletions and microduplications are performed. 239 
WGS may aid in the detection of pathogenic variants in the promotor region, introns and 240 
other non-coding regulatory elements, and provide better coverage than exome sequencing. 241 
Regulatory element disruption in microphthalmia remains largely uncharacterised.  242 
 243 
2.4 Clinical Specificity 244 
(proportion of negative tests if the disease is not present) 245 
The clinical specificity can be dependent on variable factors such as age or family history. In 246 
such cases a general statement should be given, even if a quantification can only be made 247 
case by case. 248 
 249 
2.4.1 if tested by conventional Sanger sequencing 250 
Unknown, however, if microphthalmia is not present it is unlikely that a positive test will be 251 
detected. 252 
 253 
2.4.2 if tested by Next-generation sequencing 254 
See 2.4.1. 255 
 256 
2.5 Positive clinical predictive value 257 
(life time risk to develop the disease if the test is positive) 258 
This is a congenital anomaly of the eye, therefore patients will be born with this defect, 259 
therefore nearly 100%, however variable expressivity has been noted.  260 
 261 
2.6 Negative clinical predictive value 262 
(Probability not to develop the disease if the test is negative). 263 
Assume an increased risk based on family history for a non-affected person. Allelic and 264 
locus heterogeneity may need to be considered.  265 
Index case in that family had been tested: 266 
 267 
Nearly 100%. If the non-affected relative is not a carrier of an identified disease-causing 268 
mutation, they have no increased risk, except a small risk related to the prevalence in the 269 
general population. 270 
 271 
Index case in that family had not been tested: 272 
Unknown 273 
 274 
3. Clinical Utility 275 
3.1 (Differential) diagnostics: The tested person is clinically affected 276 
       (To be answered if in 1.9 "A" was marked) 277 
3.1.1 Can a diagnosis be made other than through a genetic test? 278 
 279 
No.  (continue with 3.1.4) 280 
Yes,  281 
 clinically.   282 
 imaging   283 
 endoscopy.   284 
 biochemistry.   285 
 electrophysiology.  286 
other (please describe): 
 
 287 
 288 
3.1.2 Describe the burden of alternative diagnostic methods to the patient 289 
The definition of microphthalmia is heterogenous, however an axial length (AL) of <21 mm in 290 
adults and <19 mm in a 1 year old is most widely accepted as it represents a reduction of 2 291 
SD or more below normal. Microphthalmia can be detected using ultrasound during the 292 
second trimester, or after birth in conjunction with clinical examination. Microphthalmia can 293 
be associated with microcornea, which is defined as a horizontal diameter <9mm in a 294 
newborn and <10mm in children 2 years and older. Posterior microphthalmia is a rare subset 295 
of microphthalmia in which the total axial length of the eyeball is reduced whilst anterior 296 
segment dimensions including corneal diameter, anterior chamber depth and anteroposterior 297 
length of the lens are normal, also detected by ultrasound. Nanophthalmia, a second rare 298 
subset of microphthalmia, is classically distinguished from posterior microphthalmia based 299 
on the presence of decreased anterior chamber dimensions.     300 
  301 
Although a diagnosis of microphthalmia can be made relatively easily and cost-effectively, if 302 
this anomaly is seen, children should be investigated within a multi-disciplinary team, 303 
including Paediatricians and Clinical Geneticists, to ensure this is not part of a syndrome. 304 
Further monitoring may be required as syndromic manifestations may present later in 305 
childhood.   306 
 307 
3.1.3 How is the cost effectiveness of alternative diagnostic methods to be judged?  308 
Clinical examination and ultrasound imaging provides a cost-effective diagnosis.  309 
 310 
3.1.4 Will disease management be influenced by the result of a genetic test? 311 
No.  312 
 313 
Yes.  314 
 Therapy (please describe)  315 
 Prognosis (please describe)  Yes if a variant in a gene is associated with a 316 
syndrome, it may lead to search for systemic 317 
involvement to prevent morbidity and maximise function 318 
e.g. patients with SOX2 anophthalmia syndrome suffer 319 
from a range of multisystem abnormalities including 320 
seizures and sensorineural deafness, hence early 321 
diagnosis will lead to prompt supportive treatment, 322 
having long-term health economic benefits. 323 
 Management (please describe) Microphthalmia should be managed by 324 
specialists with expertise in this condition. If visual 325 
function is present, this must be maximised by 326 
correcting refractive error and preventing amblyopia. 327 
Those with poor vision must be supported by low visual 328 
aids and training. MRI imaging of the brain is required 329 
to rule out any associated midline neurological or 330 
pituitary defects. Referral to neurology and 331 
endocrinology may be indicated.  If a child has a non-332 
seeing eye, cosmesis can be addressed by fitting 333 
cosmetic shells or contact lenses. Socket expansion in 334 
severe microphthalmia may be indicated using 335 
enlarging conformers. Although genetic counselling can 336 
be challenging due to the extensive range of disease-337 
associated genes and variable expressivity, appropriate 338 
counselling can be applied if the mode of inheritance is 339 
identified and should be offered to the family.  340 
 341 
 342 
3.2 Predictive Setting: The tested person is clinically unaffected but carries an 343 
increased risk based on family history 344 
3.2.1 Will the result of a genetic test influence lifestyle and prevention? 345 
If the test result is positive (please describe)  346 
Microphthalmia is a congenital eye anomaly therefore if it is not clinically present at birth 347 
then this will not develop later in life. However if an individual is clinically unaffected but is a 348 
carrier, this information will inform family planning if the mode of inheritance can be 349 
identified.  350 
If the test result is negative (please describe)  351 
If the clinically unaffected person has a negative test result, no further follow-up is required. 352 
The result will inform family planning. 353 
 354 
3.2.2 Which options in view of lifestyle and prevention does a person at-risk have if no 355 
genetic test has been done (please describe)? 356 
Vision can be variably affected in microphthalmic patients depending on the severity of the 357 
anomaly and the other complex features. This may limit schooling and professions that 358 
require perfect vision. Hence, a clinically confirmed diagnosis can help to provide guidance 359 
on career choice.  360 
 361 
 362 
3.3 Genetic risk assessment in family members of a diseased person 363 
 364 
3.3.1 Does the result of a genetic test resolve the genetic situation in that family? 365 
Yes, although there may be variable expressivity, non-penetrance and germ-line mosaicism, 366 
which will complicate the advice that can be given.   367 
 368 
3.3.2 Can a genetic test in the index patient save genetic or other tests in family 369 
members? 370 
 371 
If a disease-causing mutation is identified in the index patient, family members can be tested 372 
but ophthalmic examination is also helpful. Test negative family members, who are clinically 373 
unaffected, do not need any further investigation or monitoring. 374 
  375 
3.3.3 Does a positive genetic test result in the index patient enable a predictive test in 376 
a family member? 377 
Yes, if the variant is known. 378 
 379 
 380 
3.4 Prenatal diagnosis 381 
     (To be answered if in 1.9 "D" was marked) 382 
3.4.1 Does a positive genetic test result in the index patient enable a prenatal 383 
diagnosis? 384 
Yes. Germline mosaicism and/or variable penetrance render the prediction of recurrence risk 385 
difficult in monogenic microphthalmic individuals, however molecular genetic studies for 386 
known variants are possible on amniotic fluid foetal cells withdrawn after 14 weeks of 387 
gestation or on chronic villus sampling at 10 to 12 weeks gestation and can facilitate the 388 
diagnosis of microphthalmia. Additionally, trans-vaginal ultrasonography enables the 389 
detection of microphthalmia from 12 weeks gestation (28); the maximal coronal or axial 390 
planes of the orbit are measured and compared to established eye growth charts (29).  391 
 392 
 393 
4. If applicable, further consequences of testing 394 
Please assume that the result of a genetic test has no immediate medical consequences. Is 395 
there any evidence that a genetic test is nevertheless useful for the patient or his/her 396 
relatives? (Please describe) 397 
Beyond potentially defining recurrence risk information dependent on the cause and mode of 398 
inheritance, identifying the genetic aetiology may guide genetic counselling. It also 399 
contributes to the classification of syndromic or non-syndromic microphthalmia, thereby 400 
guiding any subsequent investigations for affected patients. 401 
 402 
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 533 
1. Name of the Disease (Synonyms): 534 
Non-syndromic (isolated and complex) microphthalmia; MCOP 535 
 536 
2. OMIM# of the Disease:  537 
251600; 610093; 611038; 613094; 611040; 613517; 613704; 615113; 300345; 605738; 538 
610092; 251505; 611638; 613703; 614497; 601186; 615145; 616428; 156900; 156850; 539 
600165; 609549; 611897; 615972 540 
3. Name of the Analysed Genes or DNA/Chromosome Segments: 541 
VSX2; RAX; GDF6; MFRP; PRSS56; GDF3; ALDH1A3; SHH; GDF6; ABCB6; STRA6; 542 
TENM3; RBP4; MFRP; TMEM98 543 
 544 
4. OMIM# of the Gene(s): 545 
142993; 601881; 601147; 606227; 613858; 606522; 600463; 142993; 600725; 601147; 546 
605452; 610745; 610083; 180250; 606227; 615949 547 
 548 
Review of the analytical and clinical validity as well as of the clinical utility of DNA-based 549 
testing for mutations in the VSX2, RAX, GDF6, MFRP, PRSS56, GDF3, ALDH1A3, SHH, 550 
GDF6, ABCB6, STRA6, TENM3, RBP4, MFRP and TMEM98 genes in   551 
 diagnostic,  552 
      predictive and  553 
      prenatal settings and for  554 
      risk assessment in relatives. 555 
 556 
